ArticleAnnals of the rheumatic diseases2021

Response to: 'Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka

Yoshiya Tanaka et al.PubMed ↗Publisher ↗

No numbers read from the abstract.